Samsung Biologics Earns MSCI ESG 'A' Rating, Strengthening Its Position in Sustainable CDMO Leadership
Samsung Biologics has earned an 'A' rating in the latest Morgan Stanley Capital International (MSCI) ESG Ratings assessment this year, reflecting the company’s continuous, tangible advancements across its environmental stewardship, workplace standards, and corporate governance.
Samsung Biologics has demonstrated consistent year-over-year improvement in its MSCI ESG Ratings since first receiving a ‘B’ rating in 2023. The company has subsequently advanced its rating each year, reaching an ‘A’ rating in 2026. This continued improvement reflects the company’s ongoing efforts to strengthen its ESG management across its operations.
On the environmental front, Samsung Biologics secured the top score in its peer group. As the industry's focus broadened from carbon mitigation to comprehensive toxic emissions and waste management, the company’s hazardous materials management practices contributed positively to its environmental performance.
In the social pillar, MSCI acknowledged the company's continued focus on workforce development. This includes robust, job-specific training programs designed to develop biotechnology talent, as well as grievance-handling processes that support a highly collaborative workplace culture. In governance, Samsung Biologics continued to demonstrate strong corporate ethics and compliance practices through rigorous internal audits and dedicated compliance oversight functions.
This achievement validates the company's continued efforts to strengthen ESG management and embed ESG principles across its CDMO operations, in line with evolving sustainability expectations across the global healthcare industry. Moving forward, Samsung Biologics remains committed to transparent disclosure and to continually enhancing its sustainability reporting in alignment with global frameworks.
Samsung Biologics has earned an 'A' rating in the latest Morgan Stanley Capital International (MSCI) ESG Ratings assessment this year, reflecting the company’s continuous, tangible advancements across its environmental stewardship, workplace standards, and corporate governance.
Samsung Biologics has demonstrated consistent year-over-year improvement in its MSCI ESG Ratings since first receiving a ‘B’ rating in 2023. The company has subsequently advanced its rating each year, reaching an ‘A’ rating in 2026. This continued improvement reflects the company’s ongoing efforts to strengthen its ESG management across its operations.
On the environmental front, Samsung Biologics secured the top score in its peer group. As the industry's focus broadened from carbon mitigation to comprehensive toxic emissions and waste management, the company’s hazardous materials management practices contributed positively to its environmental performance.
In the social pillar, MSCI acknowledged the company's continued focus on workforce development. This includes robust, job-specific training programs designed to develop biotechnology talent, as well as grievance-handling processes that support a highly collaborative workplace culture. In governance, Samsung Biologics continued to demonstrate strong corporate ethics and compliance practices through rigorous internal audits and dedicated compliance oversight functions.
This achievement validates the company's continued efforts to strengthen ESG management and embed ESG principles across its CDMO operations, in line with evolving sustainability expectations across the global healthcare industry. Moving forward, Samsung Biologics remains committed to transparent disclosure and to continually enhancing its sustainability reporting in alignment with global frameworks.
Share article
Related Content